ALNY
Alnylam Pharmaceuticals Inc
251.70$
+3.0%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 454.5% | 804.0% | 980.0% | 643.0% | 2.4% | 11.4% | 15.8% | 16.6% | 16.3% | 17.0% | 14.4% | 18.2% | |
| 100.0% | 100.0% | 100.0% | 100.0% | 97.6% | 88.6% | 84.2% | 83.4% | 83.7% | 83.0% | 85.6% | 81.8% | |
| 376.3% | 672.8% | 810.9% | 434.5% | 674.7% | 298.1% | 132.9% | 93.8% | 85.1% | 54.9% | 50.1% | 35.7% | |
| 88.1% | 147.5% | 189.5% | 221.7% | 510.4% | 218.0% | 119.4% | 73.5% | 74.3% | 43.5% | 43.4% | 32.6% | |
| 464.3% | 820.3% | 1,000.3% | 656.2% | 1,185.2% | 516.1% | 252.3% | 167.3% | 159.4% | 98.5% | 93.5% | 68.3% | |
| -801.0% | -720.3% | -900.3% | -556.2% | -1,087.6% | -427.5% | -168.1% | -83.9% | -75.7% | -15.4% | -7.9% | 13.5% | |
| 5.1% | 14.3% | 17.6% | 13.6% | 39.1% | 49.4% | 17.1% | 16.9% | 15.0% | 6.6% | 6.3% | 6.8% | |
| -792.3% | -705.8% | -869.6% | -545.9% | -1,015.5% | -402.8% | -173.6% | -100.9% | -108.6% | -23.7% | -16.8% | 8.7% | |
| -79.5% | -60.6% | -49.7% | -28.5% | 1.1% | 0.4% | 0.5% | 0.1% | 0.4% | 0.4% | -4.4% | 0.3% | |
| -712.8% | -705.8% | -869.6% | -545.9% | -1,016.6% | -403.2% | -174.1% | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% | |
| -340.8% | -673.9% | -868.2% | -541.3% | -1,006.9% | -402.8% | -149.4% | -78.4% | -89.3% | -14.1% | -8.0% | 17.0% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.